![Bill Begien](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Bill Begien is Vice President-Investor Relations at NovaBridge Biosciences.
Mr. Begien is Senior Vice President-Investor Relations at CDT Equity, Inc. Mr. Begien was Vice President-Investor Relations at TFF Pharmaceuticals, Inc. from 2022 to 2023.
Aktive Positionen von Bill Begien
| Unternehmen | Position | Beginn |
|---|---|---|
| CDT EQUITY INC. | Investor Relations Kontakt | 01.09.2023 |
| NOVABRIDGE BIOSCIENCES | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Bill Begien
| Unternehmen | Position | Ende |
|---|---|---|
| TFF PHARMACEUTICALS, INC. | Investor Relations Kontakt | 01.10.2023 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
4
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
TFF Pharmaceuticals, Inc.
 TFF Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures inhaled dry powder drugs for the treatment of pulmonary diseases and conditions | Health Technology |
I-Mab
 I-Mab Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer and autoimmune diseases | Health Technology |
Conduit Pharmaceuticals, Inc.
 Conduit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage specialty biopharmaceutical company | Health Technology |
